TY - JOUR
T1 - Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma
T2 - Practical Guidance
AU - Barone, Giuseppe
AU - Barry, Ailish
AU - Bautista, Francisco
AU - Brichard, Bénédicte
AU - Defachelles, Anne-Sophie
AU - Herd, Fiona
AU - Manzitti, Carla
AU - Reinhardt, Dirk
AU - Rubio, Pedro M
AU - Wieczorek, Aleksandra
AU - van Noesel, Max
AU - Bautista Sirvent, Paco
N1 - © 2021. The Author(s).
PY - 2021/9
Y1 - 2021/9
N2 - Neuroblastoma is the most common extracranial solid tumour in children, accounting for 15% of all paediatric cancer deaths. High-risk neuroblastoma is a particularly challenging-to-treat form of disease that requires multimodality treatment, consisting of chemotherapy, surgery, high-dose chemotherapy with autologous haematopoietic stem cell rescue, radiotherapy and differentiation therapy. However, despite intense multimodal treatment regimens, the prognosis for this patient population remains poor. In recent years, immunotherapy with anti-disialoganglioside 2 (anti-GD2) antibodies was found to improve survival rates for patients with high-risk neuroblastoma. Based on studies led by the SIOPEN (International Society of Paediatric Oncology European Neuroblastoma) group, the anti-GD2 antibody dinutuximab beta was approved for use in high-risk neuroblastoma by the European Medicines Agency and has been implemented into the standard of care in many countries across Europe. However, immunotherapy with dinutuximab beta is associated with a number of adverse events that may be challenging for clinicians, such as pain, fever, hypersensitivity reactions and capillary leak syndrome. While these adverse events are considered manageable, there are currently no formal guidelines to support clinicians with their management. The aim of this article is to discuss the management of the most common adverse events encountered in clinical practice and to provide practical guidance to assist clinicians in minimising toxicity associated with dinutuximab beta.
AB - Neuroblastoma is the most common extracranial solid tumour in children, accounting for 15% of all paediatric cancer deaths. High-risk neuroblastoma is a particularly challenging-to-treat form of disease that requires multimodality treatment, consisting of chemotherapy, surgery, high-dose chemotherapy with autologous haematopoietic stem cell rescue, radiotherapy and differentiation therapy. However, despite intense multimodal treatment regimens, the prognosis for this patient population remains poor. In recent years, immunotherapy with anti-disialoganglioside 2 (anti-GD2) antibodies was found to improve survival rates for patients with high-risk neuroblastoma. Based on studies led by the SIOPEN (International Society of Paediatric Oncology European Neuroblastoma) group, the anti-GD2 antibody dinutuximab beta was approved for use in high-risk neuroblastoma by the European Medicines Agency and has been implemented into the standard of care in many countries across Europe. However, immunotherapy with dinutuximab beta is associated with a number of adverse events that may be challenging for clinicians, such as pain, fever, hypersensitivity reactions and capillary leak syndrome. While these adverse events are considered manageable, there are currently no formal guidelines to support clinicians with their management. The aim of this article is to discuss the management of the most common adverse events encountered in clinical practice and to provide practical guidance to assist clinicians in minimising toxicity associated with dinutuximab beta.
KW - Antibodies, Monoclonal/adverse effects
KW - Humans
KW - Immunologic Factors
KW - Immunotherapy/adverse effects
KW - Neuroblastoma/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85115159018&partnerID=8YFLogxK
U2 - 10.1007/s40272-021-00469-9
DO - 10.1007/s40272-021-00469-9
M3 - Article
C2 - 34541620
SN - 1174-5878
VL - 23
SP - 537
EP - 548
JO - Paediatric drugs
JF - Paediatric drugs
IS - 6
ER -